Open Access

Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)

  • Authors:
    • Wenjie You
    • Bin Shang
    • Jian Sun
    • Xueqing Liu
    • Lili Su
    • Shujuan Jiang
  • View Affiliations

  • Published online on: June 11, 2020     https://doi.org/10.3892/or.2020.7643
  • Pages: 424-437
  • Copyright: © You et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Checkpoint inhibitor‑based immunotherapy has exhibited unprecedented success in the treatment of advanced‑stage cancer in recent years. Several therapeutic antibodies targeting programmed death‑1 (PD‑1) or its ligand (PD‑L1) have received regulatory approvals for the treatment of multiple malignancies, including melanoma, non‑small cell lung cancer, kidney cancer and Hodgkin's lymphoma. However, a substantial proportion of patients still do not benefit from these agents, let alone the risk of immune‑associated toxicities and financial burden. Therefore, it is imperative to identify valid predictive biomarkers which can help optimize the selection of patients. In this review, a mechanism‑based interpretation of tumor PD‑L1 expression and other candidate biomarkers of response to antitumor PD‑1/PD‑L1 blockade was provided, particularly for the tumor microenvironment‑derived ‘immunomes’, and the challenges faced in their clinical use was addressed. Directions for future biomarker development and the potential of combined biomarker strategies were also proposed.

Related Articles

Journal Cover

August-2020
Volume 44 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020). Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncology Reports, 44, 424-437. https://doi.org/10.3892/or.2020.7643
MLA
You, W., Shang, B., Sun, J., Liu, X., Su, L., Jiang, S."Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)". Oncology Reports 44.2 (2020): 424-437.
Chicago
You, W., Shang, B., Sun, J., Liu, X., Su, L., Jiang, S."Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)". Oncology Reports 44, no. 2 (2020): 424-437. https://doi.org/10.3892/or.2020.7643